Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________________________________________

FORM 8-K

_____________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 8, 2024

_____________________________________________

agilon health, inc.

(Exact name of Registrant as Specified in Its Charter)

_____________________________________________

Delaware

001-40332

37-1915147

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

6210 E Hwy 290, Suite 450

Austin, TX

78723

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 562 256-3800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_____________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.01 per share

AGL

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective March 1, 2024, Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to agilon health and will transition from his role as chief medical officer (CMO). The company has initiated a comprehensive search process to identify a new CMO. Until a successor is named, Dr. Karthik Rao, senior medical director and vice president, network performance, will serve as interim CMO.

The full text of this news release is attached hereto as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits


Exhibit Number						Description

99.1						Press Release dated February 8, 2024.

104						Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			agilon health, inc.

Date:	February 8, 2024	By:	/s/ Denise V. Zamore
			Denise V. Zamore Executive Vice President, Chief Legal Officer & Corporate Secretary

Exhibit 99.1

agilon health Announces Chief Medical Officer Transition

AUSTIN, T.X., February 8, 2024 – agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to the company and will transition from his role as chief medical officer (CMO) effective March 1, 2024. agilon health has initiated a comprehensive search process to identify a new CMO. Until a successor is named, Karthik Rao, M.D., senior medical director and vice president, network performance, will serve as interim CMO. Dr. Rao and agilon’s chief clinical officer (CCO), Kevin Spencer, M.D., will co-lead the company’s clinical strategy.

“I want to express our deepest appreciation to Dr. Kornitzer for his leadership and considerable contributions to advancing our clinical, research and quality strategy at agilon health over the past four years. He has built a strong team, and we are glad to have him continue as a valued advisor,” said Steve Sell, chief executive officer, agilon health. “I am pleased to have the support of Dr. Rao as our interim chief medical officer and Dr. Spencer who serves as our chief clinical officer, both of whom play invaluable roles working with our physician partners and advancing our Total Care Model.”

Dr. Rao has a decade of experience as a practicing internal medicine physician and other roles working in value-based care. Prior to joining agilon, he worked at McKinsey & Company leading a broad range of strategy and operations work across the health care value chain with particular focus on provider groups and government organizations. Dr. Rao received his B.A. from Johns Hopkins University and holds a medical degree from Johns Hopkins University School of Medicine. He completed an internal medicine and primary care residency at Massachusetts General Hospital.

Dr. Spencer has more than 25 years of experience as a former chief executive officer (CEO) of an independent primary care practice, a practicing family medicine physician operating in value-based care and a founding agilon partner. Prior to agilon, Dr. Spencer was the CEO and chairman of Premier Family Physicians, and founder and president of the Southwest Provider Accountable Care Organization (ACO). Dr. Spencer received his medical degree from the University of Texas Health Science Center at Houston and completed his residency at the Carolinas Medical Center in North Carolina.

About agilon health

agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups and health systems transition to a value-based Total Care Model for their senior patients. agilon provides the technology, people, capital, process, and access to a peer network of 2,400+ primary care physicians that allows its physician partners to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is a trusted partner in 30+ diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information visit www.agilonhealth.com and connect with us on Instagram, LinkedIn, X and YouTube.

Contacts

Investor Contact

Matthew Gillmor

VP, Investor Relations

investors@agilonhealth.com

Media Contact

David Tauchen

Senior Director, Communications

media@agilonhealth.com

Source: agilon health

###

Document And Entity Information	Feb. 08, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Feb. 08, 2024
Entity Registrant Name	agilon health, inc.
Entity File Number	001-40332
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	37-1915147
Entity Address, Address Line One	6210 E Hwy 290
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78723
City Area Code	562
Local Phone Number	256-3800
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	AGL
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Entity Central Index Key	0001831097
Amendment Flag	false

Cover	Feb. 08, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Feb. 08, 2024
Entity Registrant Name	agilon health, inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-40332
Entity Tax Identification Number	37-1915147
Entity Address, Address Line One	6210 E Hwy 290
Entity Address, Address Line Two	Suite 450
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78723
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	AGL
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Entity Central Index Key	0001831097
Amendment Flag	false